Bright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

Stock Information for Bright Minds Biosciences Inc Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bright Minds Biosciences Inc Ordinary Shares

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
Bright Minds Announces Effective Date of Share Consolidation
Bright Minds Announces Proposed Share Consolidation
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
Bright Minds Biosciences Announces Non-Executive Director Appointment

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.